Context Capital Management’s ZyVersa Therapeutics ZVSA Stock Holding History

Context Capital Management’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,411	Closed	-$4.94M	–	452
2022 Q3	$4.94M	Hold	1,411	–	–	0.33%	91
2022 Q2	$4.91M	Sell	1,411 -18	-1%	-$62.6K	0.35%	87
2022 Q1	$4.97M	Buy	+1,429	New	+$4.94M	0.32%	88

Other funds holding ZVSA

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Context Capital Management's ZVSA Position: Q4 2022 in Review

Context Capital Management sold out of ZyVersa Therapeutics (ZVSA) in Q4 2022, closing a stake of 1,411 shares — an estimated $4.94M sold.

Context Capital Management first reported a position in ZVSA in Q1 2022 and held it in 3 quarters. The position peaked at $4.97M in Q1 2022. 2 funds tracked by Wall St. Rank hold ZVSA as of Q4 2022.

Context Capital Management reported no remaining ZyVersa Therapeutics position as of Q4 2022 after selling out during the quarter.
Context Capital Management sold 1,411 ZyVersa Therapeutics shares in Q4 2022, an estimated $4.94M.
Context Capital Management first reported a position in ZyVersa Therapeutics in Q1 2022 and held it in 3 quarters.
Context Capital Management's ZyVersa Therapeutics position peaked at $4.97M in Q1 2022.
2 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2022.

Based on Context Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.